Opinion|Videos|October 9, 2024
Clinical Utility of the Modified Friedreich Ataxia Rating Scale
Author(s)Sub Subramony, M.D.
Key Takeaways
- mFARS is designed to assess Friedreich Ataxia progression in clinical trials, focusing on motor function and disease severity.
- Its complexity and time requirements may limit routine use in everyday clinical practice.
Sub Subramony, M.D., discusses how the modified Friedreich Ataxia Rating Scale (mFARS) is valuable for monitoring disease progression in clinical trials and its applicability in everyday clinical practice for assessing patient status.
Advertisement
Episodes in this series
Video content above is prompted by the following:
The modified Friedreich Ataxia Rating Scale (mFARS) has been developed to monitor FA disease progression in clinical trials. Is mFARS useful in your everyday clinical practice?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
US Employer Health Care Costs Projected to Rise 9.5% in 2027
2
FDA Clears First Single-Biomarker Blood Test for Alzheimer
3
FDA Approves Nipocalimab-aahu as First Treatment for wAIHA
4
Lung Cancer Task Force Maps Research Roadmap to Close Survival Gap
5